Published

An Open-Label Study of Single-Dose Psilocybin for Borderline Personality Disorder With Co-Occurring Major Depressive Disorder

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Clinical Neuropharmacology
Date: 2026-07-01
Source: Crossref
DOI: 10.1097/wnf.0000000000000683
PubMed: 41973961

Authors

Grant Jon E.Boutouis Sophia O’Brien Margaret Avila Laurie Neelapu Megha Ehsan Dustin

Watch author

Derived topics and classifications

psilocybin Depression Personality Change Clinical Trial Clinical Trial

Citation graph

32 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

10.1521/pedi.1992.6.1.24 10.1521/pedi.18.3.226.35445 10.1016/j.psychres.2005.07.004 10.1016/s0140-6736(21)00476-1 10.1001/archpsyc.63.7.757 10.1176/appi.ajp.2007.07071079 10.1176/appi.ajp.2012.11091416 10.1192/bjp.bp.108.062984 10.1176/ajp.2006.163.5.833 10.1192/bjp.bp.107.037903 10.4088/jcp.08m04138yel 10.4088/jcp.v69n0412

Indexed papers citing this DOI

An Open-Label Study of Single-Dose Psilocybin for Borderline Personality Disorder With Co-Occurring Major Depressive Disorder2026-07-01

Related papers

Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study.Psychedelic medicine (New Rochelle, N.Y.) · 2026-09-01 Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025-2026)Journal of Clinical Medicine · 2026-08-12 Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and SuicidalityClinicalTrials.gov · 2026-08-12 Psychedelic Therapy for DepressionUnknown journal · 2026-08-11 A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot StudyClinicalTrials.gov · 2026-08-10 Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial.Nature medicine · 2026-08-06